The facts

  1. The programme is expected to cost up to US$2 billion in one-time restructuring charges and be largely complete by the end of 2029. The company says it will reinvest the savings, principally in developing new medicines. [1][2]

  2. Reported quarterly earnings were US$2.02 per share; Core earnings were US$2.79. Core is the company's adjusted measure. Their year-on-year increases were 23% and 17%, respectively, at actual exchange rates. [1][2]

  3. AstraZeneca maintained its 2026 forecast for mid-to-high single-digit revenue growth and low-double-digit Core earnings-per-share growth at constant exchange rates. Those forecasts use a different currency basis from reported growth. [1][2]

Still unconfirmed

  • The company did not announce a confirmed job-cut total in the checked reporting. Savings targets are not completed savings.

Sources

References support the numbered facts above. Source checks: 30 Oct 2026, 14:43 UTC.

  1. Third-quarter results: 9M and Q3 2026

    AstraZeneca / RNS, via Investegate · Primary source · 30 Oct 2026

    Actual company RNS text, tables, guidance and restructuring description read. The host's separate generated summary is not used as primary evidence. Quarter and nine-month figures, actual/CER growth, Reported/Core EPS and future savings remain distinct.

  2. AstraZeneca profit jumps 23% on cancer drugs as it unveils major savings plan

    Euronews / Quirino Mealha · Reporting · 30 Oct 2026

    Actual independent report read. It is separate from AstraZeneca and its announcement distributor. The savings target and restructuring costs are future expectations; no layoffs are declared as confirmed.

Report a factual error